$QNRX News

Last published 6d ago

6d agoQNRXQuoin Pharmaceuticals Ltd. - EXHIBIT 99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
6d agoQNRXQuoin Pharmaceuticals’ Latest NETHERTON NOW Video Details the Life of a Family Living with Netherton SyndromeGlobeNewswireQuoin (NASDAQ: QNRX) released a new NETHERTON NOW episode featuring Kristi and Kodi, a family living with Netherton Syndrome, and Dr. Moise Levy....
6d agoQNRXQuoin Pharmaceuticals’ Latest NETHERTON NOW Video Details the Life of a Family Living with Netherton SyndromeGlobeNewswireKristi and Kodi Share Their Experience Living with the Rare Genetic Skin Disease, Alongside Insights from Pediatric Dermatologist Moise Levy, MD Kodi, who lives with Netherton Syndrome, in the latest NETHERTON NOW
1w agoQNRXQuoin Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2026 Financial ResultsGlobeNewswire– Reports Positive Interim Data from Ongoing Phase 2/3 Study of QRX003 in Netherton Syndrome; Primary and Key Secondary Endpoints Achieved Statistical Significance Versus Pre-Specified Alpha-Adjusted Target –Announces
2w agoQNRXQuoin Pharmaceuticals to Announce Corporate Update and Third Quarter 2026 Financial Results on Thursday, November 5, 2026GlobeNewswireASHBURN, Va., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) (the "Company" or "Quoin"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan
3w agoQNRXQuoin Pharmaceuticals Announces Publication of Peer-Reviewed Paper on QRX003 for Netherton Syndrome in Dermatology and TherapyGlobeNewswire– Peer-Reviewed Paper Introducing QRX003 and Its Mechanism of Action in Netherton Syndrome Now Published – Case Report Details 21 Months of Compassionate Use Treatment in a Pediatric Patient – Patient’s Skin Improved
4w agoQNRXQuoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Peeling Skin SyndromeGlobeNewswire– Company on track to initiate first-ever formal clinical trial in Peeling Skin Syndrome before year end – Orphan Drug designation milestone provides 10 years of market exclusivity for Peeling Skin Syndrome in Europe
2mo agoQNRXQuoin Pharmaceuticals Releases New NETHERTON NOW Video: Aminah’s Story Featuring Laura Wright-Sexton, MD, the Physician Who First Met Her Daughter in the ICUGlobeNewswireASHBURN, Va., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) ("Quoin" or the "Company"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan
2mo agoQNRXCORRECTION -- Quoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Peeling Skin SyndromeGlobeNewswireSecond Rare Pediatric Disease (RPD) Designation for QRX003FDA Previously Granted RPD Designation for QRX003 in Netherton SyndromeIf a New Drug Application (NDA) for QRX003 Is Approved for Peeling Skin Syndrome, Quoin
2mo agoQNRXQuoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Peeling Skin SyndromeGlobeNewswireSecond Rare Pediatric Disease (RPD) Designation for QRX003FDA Previously Granted RPD Designation for QRX003 in Netherton SyndromeIf a New Drug Application (NDA) for QRX003 Is Approved for Peeling Skin Syndrome, Quoin
2mo agoQNRXQuoin Pharmaceuticals Reports Positive Interim Data from Ongoing Phase 2/3 Study of QRX003 in Netherton SyndromeGlobeNewswireInterim Analysis of the First Six Patients to Complete 12 Weeks of Treatment Met Pre-Specified Alpha Adjusted Target for Primary Endpoint with Statistical Significance Four of Six (66.7%) Participants Achieved the
2mo agoQNRXQuoin Pharmaceuticals Announces Private Placement Financing of Up to $50.0 MillionGlobeNewswireASHBURN, Va., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) (the "Company" or "Quoin"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan
3mo agoQNRXQuoin Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2026 Financial ResultsGlobeNewswire– Receives FDA Conditional Approval of QYLEKI™ as the Proposed Brand Name for QRX003 for Netherton Syndrome – Reports Positive Clinical Update from Ongoing Pediatric Compassionate Use Program in Netherton Syndrome –
3mo agoQNRXQuoin Pharmaceuticals to Announce Corporate Update and Second Quarter 2026 Financial Results on Friday, August 14, 2026GlobeNewswireASHBURN, Va., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) (the "Company" or "Quoin"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan
4mo agoQNRXQuoin Pharmaceuticals Receives FDA IND Clearance to Initiate Phase 2 Study of QRX003 in Peeling Skin SyndromeGlobeNewswireQuoin Expects to Initiate Phase 2 Study in 2H 2026, Study Plans to Enroll 6-8 Pediatric and Adult Patients in the U.S. and EuropeFDA Expressed No Safety Concerns Over Study Design and Duration of DosingFirst-Ever Formal
4mo agoQNRXQuoin Pharmaceuticals Receives U.S. Notice of Allowance for Patent Covering Combination Treatment for Netherton SyndromeGlobeNewswireASHBURN, Va., June 30, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) ("Quoin" or the "Company"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan
4mo agoQNRXQuoin Pharmaceuticals Receives FDA Conditional Approval of QYLEKI™ as the Proposed Brand Name for QRX003 for Netherton SyndromeGlobeNewswireQRX003 Holds Orphan Drug Designation in the United States, the European Union, and Japan, Plus Fast Track and Rare Pediatric Disease Designations from the FDAPivotal Phase 3 Study Expected to Initiate in the Second Half
4mo agoQNRXQuoin Pharmaceuticals Completes Establishment of Japanese Subsidiary to Advance Commercial Readiness for QRX003GlobeNewswireSupports Quoin's planned direct commercialization of QRX003 in Japan, one of its three core commercial territories Follows recent grant of Orphan Drug Designation to QRX003 by Japan's MHLW ASHBURN, Va., June 18, 2026
4mo agoQNRXQuoin Pharmaceuticals Announces Positive Clinical Update from Ongoing Pediatric Netherton Syndrome Compassionate Use ProgramGlobeNewswireFour of Six Patients Participating in the Compassionate Use Program Were Classified as ‘Improved' or ‘Significantly Improved' from Baseline Assessment Across Key Clinical Endpoints All Six Patients Are Younger than 10
5mo agoQNRXQuoin Pharmaceuticals Announces Japan's MHLW Grants Orphan Drug Designation for QRX003 in Netherton SyndromeGlobeNewswire-Designation provides regulatory and development incentives in Japan, including up to 10 years of market exclusivity upon approval- -Follows Orphan Drug Designation, Pediatric Rare Disease Designation, and Fast Track
5mo agoQNRXQuoin Pharmaceuticals Submits IND Application for QRX003 in Peeling Skin SyndromeGlobeNewswire-First ever IND submission for this disease, which has no current treatment or cure- -Quoin plans Phase 2 study initiation in 2H 2026- -Submission supported by positive initial clinical data from Investigator-led
6mo agoQNRXQuoin Pharmaceuticals Provides Corporate Update and Reports First Quarter 2026 Financial ResultsGlobeNewswire– Filed Breakthrough Medicine Designation Application with Saudi FDA for QRX003 in Netherton Syndrome – Submitted Application to Japanese MHLW for Orphan Drug Designation (ODD) for QRX003; MHLW Confirmed QRX003
6mo agoQNRXQuoin Pharmaceuticals to Announce Corporate Update and First Quarter 2026 Financial Results on Thursday, May 7, 2026GlobeNewswireASHBURN, Va., April 30, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) (the "Company" or "Quoin"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan
6mo agoQNRXCORRECTION -- Quoin Pharmaceuticals Provides Clinical and Regulatory Update for QRX009 Topical Rapamycin Development ProgramsGlobeNewswireCompany Planning Multi-Pronged Approach for QRX009 Including Several Investigator Led Clinical Studies in Key Indications. Company to Initiate Investigator Led Clinical Study in Pachyonychia Congenita Study Will be
6mo agoQNRXQuoin Pharmaceuticals Provides Clinical and Regulatory Update for QRX009 Topical Rapamycin Development ProgramsGlobeNewswireCompany Planning Multi-Pronged Approach for QRX009 Including Several Investigator Led Clinical Studies in Key Indications. Company to Initiate Investigator Led Clinical Study in Pachyonychia Congenita Study Will be
7mo agoQNRXQuoin Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial ResultsGlobeNewswire– Closes Private Placement Financing of Up to $104.5 Million – Secures Orphan Drug Designations for QRX003 for Netherton Syndrome (NS) in the U.S. and Europe – Advances Proposed Expedited Regulatory Approval Pathways
7mo agoQNRXQuoin Pharmaceuticals Provides Clinical and Regulatory Update from Constructive Type C Meeting with U.S. FDA for QRX003 in Netherton SyndromeGlobeNewswireFDA indicated that a single Phase 3 study may be sufficient to support marketing approval in the U.S. FDA expressed openness to an alternative study design for Phase 3 that would likely not include a traditional upfront
8mo agoQNRXNETHERTON NOW Recognizes Rare Disease Day and Highlights Growing Global Awareness of Netherton SyndromeGlobeNewswireASHBURN, Va., Feb. 26, 2026 (GLOBE NEWSWIRE) -- In recognition of Rare Disease Day® 2026, Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) today highlighted the continued growth of its NETHERTON NOW awareness campaign,
9mo agoQNRXQuoin Pharmaceuticals Announces Submission to Japanese MHLW for Orphan Drug Designation for QRX003 in Netherton SyndromeGlobeNewswireConfirmation Received from MHLW That QRX003 Qualifies for Both Orphan Drug Designation and Fast Track Regulatory Review Status Quoin Initiating the Establishment of a Japanese Subsidiary to Facilitate
9mo agoQNRXQuoin Pharmaceuticals Files Breakthrough Medicine Designation Application in Saudi Arabia for QRX003 in Netherton SyndromeGlobeNewswireQRX003 could become the first ever approved treatment for Netherton Syndrome ASHBURN, Va., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) ("Quoin" or the "Company"), a late clinical-stage
1y agoQNRXQuoin Pharmaceuticals Announces Achievement of Topical Rapamycin Target Loadings for Two Proprietary Delivery TechnologiesGlobeNewswireTarget Loadings of 4% and 5% Rapamycin Achieved for Topical Lotion and Dermal Patch Delivery Technologies Respectively Clinical Trial and Stability Batch Manufacture to Commence in Q4 2025 Clinical Testing in a Number
1y agoQNRXQuoin Pharmaceuticals Announces Corporate Update and Third Quarter 2025 Financial ResultsGlobeNewswire– Private Placement Financing of Up to $105.3 Million Closed in October 2025 to Fund Operations and R&D – Sally Lawlor Appointed CFO to Support Commercialization and Financial Operations – Orphan Drug Designation
1y agoQNRXQuoin Pharmaceuticals to Provide Corporate Update and Announce Third Quarter 2025 Financial Results on Thursday, November 6, 2025GlobeNewswireASHBURN, Va., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) (the "Company" or "Quoin"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan
1y agoQNRXQuoin Pharmaceuticals Announces Recruitment of Three Additional Patients in Investigator Pediatric Netherton Syndrome Study and Provides Positive 9 month 'Whole Body' Data Update from Ongoing StudyGlobeNewswireRecruitment of Three Additional Pediatric Patients in Austria and Ireland Achieves Investigator Study TargetCurrent Pediatric Patient in Ongoing Study Has Completely Healed Skin After 9 months of ‘Whole Body'
1y agoQNRXQuoin Pharmaceuticals Announces U.S. FDA Grants Orphan Drug Designation for QRX003 in Netherton SyndromeGlobeNewswireUpon Approval of NDA Quoin Will Receive Seven Years Marketing Exclusivity for QRX003 in the US Orphan Drug Designation previously granted by the European Medicines Agency in May 2025 ASHBURN, Va., Oct. 21, 2025
1y agoQNRXQuoin Pharmaceuticals Announces Private Placement Financing of Up to $104.5 MillionGlobeNewswireASHBURN, Va., Oct. 10, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) (the "Company" or "Quoin"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today
1y agoQNRXQuoin Pharmaceuticals Releases Fifth NETHERTON NOW Video Featuring Writers and Influencers Allie and Kaleigh Fasanella, Twin Sisters Living with Netherton SyndromeGlobeNewswireASHBURN, Va., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) ("Quoin" or the "Company"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today
1y agoQNRXQuoin Pharmaceuticals' NETHERTON NOW Campaign Surpasses One Million Video Views, Amplifying Global Awareness of Netherton SyndromeGlobeNewswireASHBURN, Va., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) ("Quoin" or the "Company"), a clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today
1y agoQNRXQuoin Pharmaceuticals Appoints New Chief Financial Officer to Support Commercialization StrategyGlobeNewswireASHBURN, Va., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) ("Quoin" or the "Company"), a late clinical stage specialty pharmaceutical company focused on rare and orphan diseases, today
1y agoQNRXQuoin Pharmaceuticals Releases Fourth Episode in NETHERTON NOW Video Series Featuring International Patient Advocate Mandy Aldwin-EastonGlobeNewswireASHBURN, Va., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) ("Quoin" or the "Company"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today
1y agoQNRXQuoin Pharmaceuticals Announces Second Quarter 2025 Financial Results and Corporate UpdateGlobeNewswire- Positive 6 Month Clinical Data Reported for Ongoing Pediatric Netherton Syndrome Study - FDA Clears Second Pivotal Study of QRX003 for Netherton Syndrome - Initial Positive Data Announced from Peeling Skin
1y agoQNRXQuoin Pharmaceuticals to Announce Second Quarter 2025 Financial Results on Thursday, August 7, 2025GlobeNewswireASHBURN, Va., July 31, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) (the "Company" or "Quoin"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan
1y agoQNRXQuoin Pharmaceuticals Provides Product Portfolio UpdateGlobeNewswireLead Product, QRX003, Being Tested in Two Active Registrational Clinical Studies for Netherton Syndrome Across the U.S., Europe, and the Middle East. QRX003 Peeling Skin Syndrome Clinical Program Continues Following
1y agoQNRXQuoin Pharmaceuticals Releases New NETHERTON NOW Video Featuring Professor Jemima Mellerio, International Expert in Genetic Skin DiseasesGlobeNewswireASHBURN, Va., June 26, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) ("Quoin" or the "Company"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today
1y agoQNRXQuoin Pharmaceuticals Announces FDA Clearance to Initiate Second Pivotal Whole Body QRX003 Netherton Syndrome Clinical StudyGlobeNewswireStudy CL-QRX003-002 will test whole-body application of QRX003 in conjunction with off-label systemic therapy in approximately 12-15 subjects.Study CL-QRX003-002 complements first whole-body pivotal study, CL-QRX003-003,
1y agoQNRXQuoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Netherton SyndromeGlobeNewswireCompany continues to advance QRX003 in late-stage clinical trials in Netherton Syndrome patients Regulatory milestone provides 10 years of market exclusivity in Europe upon approval ASHBURN, Va., May 20, 2025
1y agoQNRXQuoin Pharmaceuticals Announces Initial Positive Clinical Data for QRX003 from Pediatric Peeling Skin Syndrome StudyGlobeNewswireClear Improvement in Patient's Skin Appearance Observed in Study after 12 weeks Compared to BaselineKey endpoints including Investigator's Global Assessment (IGA), Modified Ichthyosis Area Severity (M-IASI) and
1y agoQNRXQuoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2025 Financial ResultsGlobeNewswireContinued Progress in Ongoing Late-Stage Netherton Syndrome Studies Announced Positive Clinical Data for Adult and Pediatric Netherton Patients Provided Clear Visual Evidence of QRX003 Mechanism of Action Patent
1y agoQNRXQuoin Pharmaceuticals to Announce First Quarter 2025 Financial Results on Tuesday, May 13, 2025GlobeNewswireASHBURN, Va., May 06, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) (the "Company" or "Quoin"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan
1y agoQNRXQuoin Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price RuleGlobeNewswireASHBURN, Va., April 30, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) (the "Company" or "Quoin"), a late clinical stage, specialty pharmaceutical company focused on the development and